Xeris Biopharma Holdings (XERS) Net Equity Issued and Repurchased (2021 - 2022)
Xeris Biopharma Holdings' (XERS) quarterly Net Equity Issued and Repurchased came in at $30.0 million in Q1 2022, up 11.11% on a YoY basis from $27.0 million in Q1 2021, and up 11.11% quarter-over-quarter from $27.0 million in Q1 2021.
Powered by 
Analysis
Xeris Biopharma Holdings (XERS) Net Equity Issued and Repurchased (2021 - 2022) Analysis & Trends
Xeris Biopharma Holdings (XERS) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $30.0 million the latest figure, recorded in Q1 2022.
- For the quarter ending Q1 2022, Net Equity Issued and Repurchased rose 11.11% year-over-year to $30.0 million; the trailing twelve-month figure through Dec 2022 stood at $30.0 million (up 11.11% YoY), and the FY2022 full-year result was $30.0 million, up 11.11% from the prior year.
- Net Equity Issued and Repurchased grew to $30.0 million in Q1 2022 per XERS's latest filing, from $27.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $30.0 million in Q1 2022 and bottomed at $27.0 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | - |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | - |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | 141.90 Mn |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | - |
| 10 | Xeris Biopharma Holdings | 1.37 Bn | 1.25 Bn | 79.59 Mn | - |